Weight management

Weight management is the area where peptide science has produced its most striking, best-evidenced results, and also some of its most overhyped research chemicals. The contrast between the two is the most useful thing to understand here.

On the strong-evidence side are the incretin medicines: Semaglutide (a GLP-1 receptor agonist) and Tirzepatide (a dual GIP/GLP-1 agonist) are approved by the FDA and EMA for chronic weight management, with large randomized trials behind them. Retatrutide, a triple agonist, has shown even larger weight loss in trials, but it is investigational and not approved, available only within clinical studies.

On the weaker-evidence side, AOD-9604 — a growth-hormone fragment once developed as an obesity drug — failed to show significant weight loss versus placebo in its human trials and was discontinued for that use. Tesamorelin reduces visceral fat but only in its narrow approved HIV-lipodystrophy indication.

Each entry below covers mechanism, trial results (including negative ones), approval status, and risks.

Conditions people ask about

Popular videos in this area promise to "reverse," "fix at the root," or "cure" metabolic conditions with a peptide protocol — that framing is not supported. No compound on this site is an approved treatment for any condition below, and the dramatic reversal percentages such content cites lack completed controlled human evidence for the condition being named. The notes below exist to answer common searches honestly, not to guide treatment: they say which of our compounds are discussed in each context and what their honest status is. Any of these conditions is a matter for a licensed clinician who can diagnose and stage it — a research peptide is not a substitute for that workup or for approved care.

Insulin resistance

High-claim content frames insulin resistance as something you can "reverse" or "fix at the root" with a peptide, positioning research compounds as insulin sensitizers that outperform standard care. The reality is that insulin resistance is not a standalone disease with its own approved drug — it is a metabolic feature that appears within type 2 diabetes, prediabetes, PCOS and obesity, and the established prescription tools are approved for those diagnoses, not for "insulin resistance" as a target [Human]. Among our inventory, only the incretin drugs have controlled human data improving insulin-resistance markers, and only as a downstream effect of treating diabetes/obesity: tirzepatide is a GLP-1/GIP dual agonist approved for type 2 diabetes and obesity (not for insulin resistance itself) that reduced HOMA2-IR and improved beta-cell function in the SURPASS and SURMOUNT trials as an effect of glycemic/weight treatment [Human]; semaglutide, a GLP-1 agonist approved for type 2 diabetes and obesity, improves insulin-resistance markers within those indications but lowered HOMA-IR less than tirzepatide head-to-head in SURPASS-2, and is not indicated for insulin resistance as a diagnosis [Human]. The mitochondrial/metabolic-activator peptides marketed for this purpose have essentially no completed controlled human evidence: MOTS-c improved insulin-stimulated glucose uptake and insulin sensitivity in rodent models and is widely marketed as an insulin sensitizer, but human efficacy is unproven — a first Phase 2a trial in prediabetes/overweight only started around 2026 [Animal][Hypothesis]; 5-amino-1MQ is an NNMT inhibitor studied preclinically for fat mass and metabolic rate, with no controlled human trial showing it improves insulin resistance [Animal][In vitro]; and SLU-PP-332 is an ERR-agonist "exercise mimetic" that improved glucose handling in diet-induced-obese mice with no human data and preclinical-only status [Animal][Hypothesis]. Suspected insulin resistance needs a licensed clinician and proper diagnosis (fasting glucose/insulin, HbA1c, OGTT) — a research peptide is not a substitute for that workup or for approved therapy.

Metabolic dysfunction / fatty liver (MASLD/MASH)

High-claim content presents fatty liver as fully "reversible" with a peptide, citing dramatic liver-fat clearance percentages as if any research peptide were a proven cure for MASLD or MASH. In reality MASLD (fatty liver) and its inflammatory/fibrotic form MASH are serious progressive liver conditions, and until recently there were no approved drugs at all — the first, resmetirom (not in our inventory), was FDA-approved for MASH with fibrosis only in March 2024 [Human]. Among our inventory, only semaglutide has an actual MASH approval: the Wegovy formulation received accelerated FDA approval in August 2025 for MASH with moderate-to-advanced fibrosis, based on the phase 3 ESSENCE trial — an approval for MASH with fibrosis, not a blanket "fatty liver" cure [Human]. The others people cite are investigational or narrowly indicated: retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, cut liver fat by more than 80% relative at higher doses with steatosis resolution in most patients in a phase 2a MASLD trial, but it is not FDA-approved for any indication and long-term/fibrosis-endpoint data are still pending [Human, investigational]; tesamorelin, a GHRH analog approved only for HIV-associated visceral fat, showed reduced liver fat and less fibrosis progression over 12 months in a randomized trial — but that evidence is confined to HIV-associated NAFLD and it is not approved for general MASLD/MASH [Human, narrow]; and tirzepatide, approved for type 2 diabetes and obesity, reduces liver fat as a metabolic effect and is being studied in MASH, but here it is discussed for fatty liver rather than approved for it [Human]. Dramatic "reversal" framing overstates a still-emerging evidence base and ignores that MASH is diagnosed and staged by a hepatologist (imaging, elastography, sometimes biopsy) — a research peptide is not a substitute for that diagnosis or for licensed care.